1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Diabetic Macular Edema (DME) - Epidemiology Forecast to 2030

Diabetic Macular Edema (DME) - Epidemiology Forecast to 2030

  • May 2021
  • 125 pages
  • ID: 6071725
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Diabetic macular edema (DME)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted DME epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

DME Understanding
DME is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in the developed and other developing countries. DR is caused by long-term damage to the retina’s small blood vessels. The leakage of fluid into the retina may lead to swelling of the surrounding tissue, including the macula. If left untreated, fluid can leak into the macula’s center, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called DME. The definition of clinically significant macular edema (CSME) is the most significant outcome of the Early Treatment Diabetic Retinopathy Study (ETDRS); it established a method for classifying and diagnosing DME and determining when treatment is required. Previously, DME was defined as CSME or not, and focal laser treatment was initiated only for CSME. Then, DME was subcategorized into two main categories: focal diabetic macular edema (fDME) and diffuse diabetic macular edema (dDME). DME diagnosis is clinically performed by fundoscopy; when the center of the macula (fovea centralis) is thickened or swollen, this is referred to as a clinically significant central-involved macular edema (CI-CSME). It is referred to as a clinically significant non-central-involved macular edema (NCI-CSME) when it is unaffected. Apart from this, tests that help in the diagnosis of DME are visual acuity, refractive error examination, fluorescein angiography (FA), optical coherence tomography (OCT) scan, pupil examination, slit-lamp examination, and retinal examination. However, if the diagnosis is delayed or the condition is left untreated, complications can arise and may even permanently impair the vision.
Epidemiology Perspective
The DME epidemiology division provides the insights about historical and current DME patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In 2020, the overall prevalent cases of DME accessed to be around 1,862,529 in the 7MM, which are expected to grow during the forecast period, i.e., 2021–2030.
The disease epidemiology covered in the report provides historical as well as forecasted DME epidemiology [segmented as Total Prevalent cases of DME, Total Diagnosed Prevalent cases of DME, Gender-specific Diagnosed Prevalent Cases of DME, Age-specific Diagnosed Prevalent Cases of DME, Subgroups-Specific Diagnosed Prevalent Cases of DME and Treated cases of DME] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2030.

Country Wise- DME Epidemiology
• In the United States, the total number of prevalent cases of DME were 1,026,346 in 2020 which are expected to increase during the forecast period, i.e., 2021–2030.
• In 2020, the total prevalent cases of DME were 641,864 in EU-5, which are projected to increased during the forecast period, i.e., 2021–2030.
• In Japan, the total number of prevalent cases of DME were 194,319 in 2020 which are expected to grow during the forecast period, i.e., 2021–2030.
• Findings from various secondary studies suggest that DME affects more males as compared to females, and is more prevalent in elderly population. In the 7MM, the gender-specific diagnosed cases of DME were 486,120 for males and 352,018 for females, in 2020. In the 7MM, the age-specific diagnosed prevalent cases of DME were 120,436, 363,767 and 353,935 for the age-groups 18-44, 45-64 and ?75 year, in 2020.
• In 2020, 193,979 non-central involved cases of DME and 267,876 central-involved DME cases were observed in the United States.

Scope of the Report
• The DME report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
• The DME Report and Model provide an overview of the risk factors and global trends of DME in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of DME in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of DME.
• The report provides the segmentation of the DME epidemiology by total prevalent cases in the 7MM.
• The report provides the segmentation of the DME epidemiology by diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the DME epidemiology by gender-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the DME epidemiology by age-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the DME epidemiology by subgroups-specific diagnosed prevalent cases of DME in the 7MM.
• The report provides the segmentation of the DME epidemiology by treated cases of DME in the 7MM.

Report Highlights

• 10-Year Forecast of DME epidemiology
• 7MM Coverage
• Epidemiology Segmentation
KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over DME scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to DME?
• What are the key findings pertaining to the DME epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
• What would be the total number of patients of DME across the 7MM during the study period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of DME?

Reasons to buy
The DME Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global DME market
• Quantify patient populations in the global DME market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for DME therapeutics in each of the markets covered
• Understand the magnitude of DME population by its severity
• The DME epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The DME Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on